New hope for kidney cancer: experimental combo targets resistant tumors
NCT ID NCT06730932
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug called JS004, a BTLA antibody, combined with toripalimab (an immunotherapy) in 31 people with advanced kidney cancer that has worsened after prior immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progression. Participants receive both drugs intravenously every three weeks for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BTLA monoclonal antibody (JS004) combined with toripalimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced kidney cancer who have stopped responding to standard immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 31 participants and no comparison group. The treatment may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR ADVANCED CLEAR CELL RENAL CELL CARCINOMA THAT HAS PROGRESSED AFTER PREVIOUS IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China